Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$8.43 +5.0%	$7.30	$2.05 ▼ $8.72	$716.01M	-0.46	935,930 shs	1.26 million shs
ARWR Arrowhead Pharmaceuticals	$20.75 +2.7%	$16.99	$9.57 ▼ $27.34	$2.79B	0.94	2.26 million shs	2.42 million shs
IMVT Immunovant	$14.84 +0.1%	$16.39	$12.72 ▼ $34.47	$2.58B	0.66	1.36 million shs	1.10 million shs
NAMS NewAmsterdam Pharma	$24.44 +0.5%	$21.60	$14.06 ▼ $27.29	$2.74B	-0.02	800,849 shs	728,797 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+2.69%	-3.25%	-2.19%	+49.81%	+255.31%
ARWR Arrowhead Pharmaceuticals	+1.71%	+1.05%	+37.32%	+31.25%	-14.41%
IMVT Immunovant	0.00%	-6.73%	-16.27%	+1.79%	-52.98%
NAMS NewAmsterdam Pharma	-0.53%	-5.59%	+7.80%	+33.04%	+49.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.4465 of 5 stars	4.5	2.0	0.0	2.2	2.5	0.6
ARWR Arrowhead Pharmaceuticals	3.6873 of 5 stars	3.5	1.0	3.4	2.6	2.5	0.0
IMVT Immunovant	2.9303 of 5 stars	4.4	2.0	0.0	2.6	1.7	0.0
NAMS NewAmsterdam Pharma	3.5538 of 5 stars	4.4	1.0	0.0	2.7	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	39.38% Upside
ARWR Arrowhead Pharmaceuticals	3.00	Buy	$43.14	107.92% Upside
IMVT Immunovant	2.83	Moderate Buy	$35.20	137.20% Upside
NAMS NewAmsterdam Pharma	2.89	Moderate Buy	$41.20	68.58% Upside

Current Analyst Ratings Breakdown

Latest AMLX, ARWR, NAMS, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
8/7/2025	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$38.00 ➝ $39.00
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/17/2025	NAMS NewAmsterdam Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$27.00
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	8.60	N/A	N/A	$1.88 per share	4.48
ARWR Arrowhead Pharmaceuticals	$3.55M	808.14	N/A	N/A	$3.76 per share	5.52
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.49 per share	N/A
NAMS NewAmsterdam Pharma	$45.56M	60.42	N/A	N/A	$6.91 per share	3.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$2.50	N/A	N/A	N/A	N/A	-82.48%	-70.15%	11/6/2025 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.28	N/A	N/A	N/A	N/A	-40.91%	-11.62%	N/A
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.62	N/A	N/A	N/A	-259.07%	-27.27%	-25.00%	11/5/2025 (Estimated)

Latest AMLX, ARWR, NAMS, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.44	-$0.46	-$0.02	-$0.46	N/A	N/A
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million
8/6/2025	Q2 2025	NAMS NewAmsterdam Pharma	-$0.52	-$0.15	+$0.37	-$0.15	$1.44 million	$19.15 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	8.72	8.72
ARWR Arrowhead Pharmaceuticals	0.39	4.87	4.87
IMVT Immunovant	N/A	12.32	12.32
NAMS NewAmsterdam Pharma	N/A	21.08	21.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
ARWR Arrowhead Pharmaceuticals	62.61%
IMVT Immunovant	47.08%
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	12.30%
ARWR Arrowhead Pharmaceuticals	4.30%
IMVT Immunovant	1.80%
NAMS NewAmsterdam Pharma	20.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.17 million	78.20 million	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.26 million	132.31 million	Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
NAMS NewAmsterdam Pharma	4	112.63 million	89.16 million	Optionable

AMLX, ARWR, NAMS, and IMVT Headlines

Recent News About These Companies

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

August 21 at 2:41 AM | prnewswire.com

NewAmsterdam Pharma’s EMA Validation for Obicetrapib

August 19 at 7:38 AM | msn.com

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

August 18 at 8:00 AM | globenewswire.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Buys 471 Shares

August 15, 2025 | marketbeat.com

Insider Buying: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director Purchases 471 Shares of Stock

August 14, 2025 | insidertrades.com

Analysts Issue Forecasts for NAMS FY2026 Earnings

August 12, 2025 | marketbeat.com

Bullish: Analysts Just Made A Meaningful Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Forecasts

August 12, 2025 | finance.yahoo.com

William Blair Issues Optimistic Forecast for NAMS Earnings

August 12, 2025 | americanbankingnews.com

Brokerages Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Target Price at $41.20

August 11, 2025 | americanbankingnews.com

Leerink Partnrs Issues Optimistic Outlook for NAMS Earnings

August 11, 2025 | marketbeat.com

William Blair Brokers Increase Earnings Estimates for NAMS

August 11, 2025 | marketbeat.com

Scotiabank Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

August 10, 2025 | theglobeandmail.com

Analysts Are Upgrading NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) After Its Latest Results

August 9, 2025 | finance.yahoo.com

NewAmsterdam Pharma (NASDAQ:NAMS) Trading 10.1% Higher Following Analyst Upgrade

August 9, 2025 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 9, 2025 | marketbeat.com

Royal Bank Of Canada Issues Positive Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price

August 8, 2025 | marketbeat.com

What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co

August 8, 2025 | benzinga.com

CenterBook Partners LP Purchases 13,675 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

August 8, 2025 | marketbeat.com

NewAmsterdam Pharma Clears Key Benchmark, Hitting 80-Plus RS Rating

August 7, 2025 | msn.com

NewAmsterdam Pharma Second Quarter 2025 Earnings: US$0.15 loss per share (vs US$0.41 loss in 2Q 2024)

August 7, 2025 | finance.yahoo.com

NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

August 7, 2025 | aol.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX, ARWR, NAMS, and IMVT Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.43 +0.40 (+4.98%)

Closing price 04:00 PM Eastern

Extended Trading

$8.34 -0.09 (-1.08%)

As of 07:50 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$20.75 +0.55 (+2.72%)

Closing price 04:00 PM Eastern

Extended Trading

$20.75 0.00 (0.00%)

As of 06:22 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Immunovant NASDAQ:IMVT

$14.84 +0.02 (+0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$14.84 +0.00 (+0.01%)

As of 07:50 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

NewAmsterdam Pharma NASDAQ:NAMS

$24.44 +0.12 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$24.46 +0.02 (+0.10%)

As of 06:06 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time